|
|
Volumn 39, Issue 2, 2001, Pages 9-10
|
|
Why not ▼zanamivir?
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIBIOTIC AGENT;
IBUPROFEN;
PARACETAMOL;
PLACEBO;
ZANAMIVIR;
ADULT;
AGED;
ARTICLE;
BRONCHOSPASM;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
COST EFFECTIVENESS ANALYSIS;
DISEASE DURATION;
DRUG INDICATION;
DRUG RESEARCH;
DRUG SAFETY;
DRUG USE;
HEALTH CARE QUALITY;
HIGH RISK PATIENT;
HUMAN;
INFLUENZA;
MAJOR CLINICAL STUDY;
MEDICAL DECISION MAKING;
NATIONAL HEALTH SERVICE;
PEER REVIEW;
PRACTICE GUIDELINE;
PRESCRIPTION;
QUALITY CONTROL;
RANDOMIZED CONTROLLED TRIAL;
RISK ASSESSMENT;
SIDE EFFECT;
SYMPTOMATOLOGY;
|
|
EID: 0035109611
PISSN: 00126543
EISSN: None
Source Type: Journal
DOI: 10.1136/dtb.2001.3929 Document Type: Article |
|
Times cited : (11)
|
|
References (9)
|
